newdrugapprovals.org
GSK and Genmab seek FDA approval for ofatumumab combination therapy for CLL first-line treatment
GlaxoSmithKline (GSK) and Genmab have submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) seeking the use of Arzerra (ofatumumab) in combinati…